A national study for blood based response monitoring of newly diagnosed DLBCL patients

Recruiting

• Conditions: Aggressive B-cell Lymphoma; non-Hogkin Lymphoma; 10025320

• Registration Number: NL-OMON52589
• Lead Sponsor: HOVO

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 250

Inclusion Criteria

*Patients diagnosed with newly diagnosed DLBCL (including HGBCL- NOS and
HGBCL-DH) according to WHO classification 2016
* Ann Arbor stage II-IV
* Patients intended to be treated with 6 cycles R-CHOP (or DA-EPOCH-R) as
first-line treatment (successive inclusion in HOVON 151 or HOVON 152 is
possible)
* Age >= 18 years

Exclusion Criteria

* Patients with limited stage II disease planned to receive 3 cycles of R-CHOP
+ radiotherapy, or 4 x R-CHOP+ 2R

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The realisation of a reliable blood based assay that identifies primary<br /><br>refractory and early relapsing patients with DLBCL treated in first-line.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The realisation of a database that integrates the data of the blood based assay<br /><br>to the clinical data and to molecular pre-treatment tissue profiles </p><br>